

Announcement of agreement on collaborative development of automated-Specific  
Immuno-monitoring System for cancer immunotherapy

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, “OncoTherapy”) announces that OncoTherapy and Panasonic Healthcare Co., Ltd (President: Kenji Yamane; hereinafter, “Panasonic Healthcare”) have agreed on the collaborative development of the automated immune monitoring system for evaluation of the effect of cancer immunotherapy (“automated-Specific Immuno-monitoring System”).

OncoTherapy has constructed the immuno-monitoring system for objective evaluation of the effect of cancer immunotherapy and the standardization of the immuno-monitoring, in addition to conducting clinical development of peptide cancer vaccine. On the other hand, Panasonic Healthcare is developing various medical devices to realize personalized healthcare with comprehensive technologies of Panasonic group.

Taken together with the know-how in clinical development of OncoTherapy and advanced mechatronics and medical informatics technologies of Panasonic Healthcare, OncoTherapy and Panasonic Healthcare will jointly develop this automated system focusing on the global standardization of immuno-monitoring.

< Panasonic Healthcare Co., Ltd >

Panasonic Healthcare Co., Ltd. aims to become a solution provider to realize “personalized healthcare” by helping to link diagnosis and treatment, supporting drug research and development , and through the utilization of medical information.

- Head office: 2-38-5, Nishi-shinbashi, Minato-ku, Tokyo
- President: Kenji Yamane
- Business lineups: development, manufacture, distribution and services of blood glucose monitoring system, computer-based patient’s record system, medical devices for life science and so on.
- Capital: 7,907 million yen